ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 101 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $704,050 | -36.1% | 146,677 | 0.0% | 0.00% | -25.0% |
| Q2 2023 | $1,101,544 | +69.8% | 146,677 | +2.2% | 0.00% | +33.3% |
| Q1 2023 | $648,652 | -61.6% | 143,507 | -4.3% | 0.00% | -62.5% |
| Q4 2022 | $1,689,734 | +16.9% | 149,932 | -0.8% | 0.01% | +14.3% |
| Q3 2022 | $1,446,000 | +80.5% | 151,112 | +52.7% | 0.01% | +75.0% |
| Q2 2022 | $801,000 | +172.4% | 98,964 | +2387.2% | 0.00% | +300.0% |
| Q3 2021 | $294,000 | – | 3,979 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $92,828,000 | 21.48% |
| Vivo Capital, LLC | 4,220,048 | $40,386,000 | 4.46% |
| Logos Global Management LP | 2,971,352 | $28,436,000 | 3.50% |
| Samsara BioCapital, LLC | 262,786 | $2,515,000 | 0.59% |
| Orbimed Advisors | 2,871,000 | $27,475,000 | 0.51% |
| Cormorant Asset Management, LP | 712,079 | $6,815,000 | 0.48% |
| Pier Capital, LLC | 272,617 | $2,609,000 | 0.45% |
| Redmile Group, LLC | 752,097 | $7,198,000 | 0.28% |
| Nan Fung Group Holdings Ltd | 41,950 | $401,000 | 0.26% |
| Artal Group S.A. | 500,000 | $4,785,000 | 0.20% |